World Health Organization

Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems

Retrieved on: 
Thursday, March 7, 2024

The agreement, signed on March 4, 2024, lays the groundwork for further collaboration between Sharps and Roncadelle to develop and manufacture next-generation drug delivery products.

Key Points: 
  • The agreement, signed on March 4, 2024, lays the groundwork for further collaboration between Sharps and Roncadelle to develop and manufacture next-generation drug delivery products.
  • “We believe that this is just the beginning of Sharps’ collaboration with Roncadelle.
  • “This alliance underscores our unwavering commitment to innovation and excellence, reshaping standards within the global healthcare landscape.”
    Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
  • As part of the cooperative agreement, Sharps and Roncadelle intend to collaborate on the development of new drug delivery products.

Jhpiego pledges support to countries working to eliminate cervical cancer

Retrieved on: 
Wednesday, March 6, 2024

Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .

Key Points: 
  • Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .
  • Jhpiego is also committed in supporting at least five other countries for HPV vaccine coverage improvement and/or implementation of tailored interventions to increase HPV vaccine coverage.
  • Jhpiego has long been committed to integrated programs that link improved screening and treatment for cervical cancer as well as accelerating vaccine uptake.
  • We are inspired by these new commitments to work together across the whole spectrum of cervical cancer responses; together we have the potential to save many more women’s lives.”

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia.
  • The study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the palliative care context.
  • Psyence Australia has partnered with a noted psychedelic Contract Research Organization (CRO), iNGENū Pty Ltd ("iNGENū"), to design and execute the clinical trial.
  • Psyence anticipates enrolling the first patient in Q2 2024 and expects the primary endpoint results to be available in 2025.

GN launches The New Norm – a stigma-busting image bank that challenges misperceptions about hearing loss and hearing aids

Retrieved on: 
Sunday, March 3, 2024

BALLERUP, Denmark, March 03, 2024 (GLOBE NEWSWIRE) -- Today GN launches The New Norm, a campaign aiming to tackle the visual misperception people have of modern hearing aids, which contributes to the high level of untreated hearing loss.

Key Points: 
  • On World Hearing Day, GN is launching a stigma-busting photography campaign showcasing real people with hearing loss – from world-class athletes to award-winning musicians – wearing their modern-day hearing aids.
  • BALLERUP, Denmark, March 03, 2024 (GLOBE NEWSWIRE) -- Today GN launches The New Norm, a campaign aiming to tackle the visual misperception people have of modern hearing aids, which contributes to the high level of untreated hearing loss.
  • In response, GN, a global leader in hearing technology, worked with photographer Gala Ricote (who has worn hearing aids for over 20 years) to photograph six inspiring hearing aid wearers.
  • The New Norm image bank provides access to free, high-quality images that represent the modern era of hearing aids and celebrates life with hearing loss.

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

Retrieved on: 
Tuesday, February 27, 2024

The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.

Key Points: 
  • The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.
  • A randomized, double-blind, active-controlled, multi-center Phase 3 trial to investigate the efficacy and safety of CKDB-501A in subjects with moderate-to-severe glabellar lines was completed in South Korea on November 20, 2023 (NCT05804656).
  • “This is clinically promising to see Healis’ lead protein, CKDB-501A, pass safety and efficacy in South Korea,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • Healis Therapeutics announced a strategic partnership with CKD Bio in 2024 to develop CKDB-501A for CNS indications.

American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis

Retrieved on: 
Thursday, February 22, 2024

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and Genomics (ACMG) technical laboratory standards documentation for solid tumor analysis.

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and Genomics (ACMG) technical laboratory standards documentation for solid tumor analysis.
  • The technical laboratory standards were developed by a working group of laboratory geneticists performing cytogenetic studies.
  • “We are thrilled to see OGM included in the newest section of the ACMG technical laboratory standards for solid tumor studies, which provides a standardized guide for laboratory geneticists who are conducting this cytogenomic analysis.
  • We believe that cytogenomic analysis of solid tumor samples is critically important for clinical research,” added Erik Holmlin, PhD, president and chief executive officer of Bionano.

Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

Retrieved on: 
Wednesday, February 21, 2024

The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region.

Key Points: 
  • The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region.
  • “We are building strategic partnerships within the entire Latin American distribution network to support region-wide efforts to improve medical safety and healthcare outcomes.
  • The introduction of Securegard technology into Latin America can greatly enhance the overall quality level of healthcare available in that market.
  • For additional information on Sharps Technology and its Securegard smart safety syringes, please visit www.sharpstechnology.com .

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

Retrieved on: 
Thursday, March 7, 2024

“The WHO INN and USAN approval of nelitolimod is an important milestone in the continued progress we are making with our nelitolimod program,” said Mary Szela, Chief Executive Officer and President of TriSalus.

Key Points: 
  • “The WHO INN and USAN approval of nelitolimod is an important milestone in the continued progress we are making with our nelitolimod program,” said Mary Szela, Chief Executive Officer and President of TriSalus.
  • This approach has the potential to enable more durable responses by patients to other immunotherapeutics, thereby facilitating better patient outcomes.
  • Information on nelitolimod will be posted on the USAN website ( www.ama-assn.org/go/usan ) and will be published in the Chemical Abstracts Service and in the U.S. Pharmacopeia.
  • Going forward, TriSalus will use the name in publications and public statements, at conferences and other forums, and in corporate-related materials.

HR Solution Remofirst Raises $25 Million Series A Funding to Make it Affordable and Easy to Employ Global Remote Teams

Retrieved on: 
Wednesday, March 6, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240306357812/en/
    Remofirst cofounders Nurasyl Serik (left) and Volodymyr Fedoriv, who saw a need for a simple and affordable way for companies to legally and compliantly employ global teams, today announced $25 million in Series A venture capital funding.
  • This additional funding is a huge milestone for Remofirst, validating its vision for the future of global distributed teams and our superior solution that is affordable and easy to use.
  • The Remofirst solution leverages local in-country legal experts to ensure that its contracts are compliant in all locations, avoiding misclassification risks.
  • Prior to its Series A round, Remofirst raised $14.1 million in Seed funding in 2022.

AHF Urges WHO: Save Critical HIV Tech

Retrieved on: 
Monday, March 4, 2024

AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.

Key Points: 
  • AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.
  • “Working in 46 countries, AHF country teams are seeing the consequences of Abbott’s and BD’s decisions firsthand, particularly in Africa and Asia.
  • CD4 testing shows how HIV damages our immune system since the virus targets and destroys CD4 cells.
  • While CD4 count is not vital for HIV diagnosis, it’s extremely important upon diagnosis, as the patient’s condition may have already progressed to AIDS—thus essential to the HIV continuum of care.